This story was originally published Oct. 15.
Helicos has received a letter from Nasdaq stating that it has failed to regain compliance with the exchange's minimum bid price requirement and that its shares could be suspended on Oct. 21.
Helicos received the delisting determination letter on Oct. 12, according to documents filed on Friday with the US and Securities Exchange Commission.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
